News
AKRO
19.92
-3.91%
-0.81
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 3d ago
Akero Therapeutics Price Target Cut to $38.00/Share From $50.00 by Evercore ISI Group
Dow Jones · 3d ago
Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Benzinga · 3d ago
AKERO THERAPEUTICS INC <AKRO.O>: EVERCORE ISI CUTS TARGET PRICE TO $38 FROM $50
Reuters · 3d ago
Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Akero Therapeutics, Inc. On behalf of those who acquired Akero's securities. The lawsuit alleges that Akero made false and/or misleading statements about the results of a study of its lead drug candidate. Investors have until June 25, 2024 to apply to be appointed as a lead plaintiff in the lawsuit.
Barchart · 5d ago
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Dow Jones · 5d ago
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 5d ago
Canaccord Genuity Maintains Buy on Akero Therapeutics, Lowers Price Target to $56
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 5d ago
Positive Buy Rating for Akero Therapeutics Backed by Clinical and Operational Progress
TipRanks · 5d ago
Weekly Report: what happened at AKRO last week (0506-0510)?
Weekly Report · 5d ago
AKERO THERAPEUTICS INC <AKRO.O>: CANACCORD GENUITY CUTS TARGET PRICE TO $56 FROM $59
Reuters · 5d ago
Akero Therapeutics, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/11 05:05
AKERO THERAPEUTICS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING
Reuters · 05/10 20:58
AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.
Robbins LLP reminds investors that a shareholder filed a class action on behalf of Akero Therapeutics, Inc. (NASDAQ: AKRO) Akero is a clinical stage biopharmaceutical company. Robbins LLP is investigating allegations that Akero Misled Investors regarding the Viability and Efficacy of its trial drug candidate.
Barchart · 05/10 20:46
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024
Akero Therapeutics reported earnings per share of -90 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -95 cents. AkeroTherapeutics just reported results for first quarter.
Investorplace · 05/10 17:54
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
Glancy Prongay & Murray LLP reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action lawsuit. Akero Therapeutics, Inc. Announced the results of its Phase 2b SYMMETRY trial, revealing that the study failed to meet its primary endpoint. On October 10, 2023, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share.
Barchart · 05/10 12:12
Akero Therapeutics GAAP EPS of -$0.90 beats by $0.05
Earnings News Akero Therapeutics GAAP EPS of -$0.90 beats by $0.05. Akero's cash, cash equivalents and short-term marketable securities as of March 31, 2024, were $903.7 million. Q1 GAAP earnings per share of -0.95.
Seeking Alpha · 05/10 11:22
Akero Therapeutics Q1 EPS $(0.90) Beats $(0.95) Estimate
Benzinga · 05/10 11:15
AKERO THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 05/10 11:00
More
Webull provides a variety of real-time AKRO stock news. You can receive the latest news about Akero Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AKRO
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.